These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31849444)

  • 1. Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8).
    Horner F; Lip PL; Clark H; Chavan R; Sarmad A; Mushtaq B
    Clin Ophthalmol; 2019; 13():2461-2467. PubMed ID: 31849444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
    Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
    Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice.
    Debourdeau E; Beylerian H; Nguyen V; Barthelmes D; Gillies M; Gabrielle PH; Vujosevic S; Otoole L; Puzo M; Creuzot-Garcher C; Wolff B; Daien V;
    Ophthalmol Ther; 2024 Jul; ():. PubMed ID: 38976148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years' Real-World Clinical Outcomes.
    Horner F; Lip PL; Mohammed BR; Fusi-Rubiano W; Gokhale E; Mushtaq B; Chavan R
    Clin Ophthalmol; 2021; 15():1703-1713. PubMed ID: 33935487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
    Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
    BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration.
    Chandra S; Rasheed R; Menon D; Patrao N; Lamin A; Gurudas S; Balaskas K; Patel PJ; Ali N; Sivaprasad S
    Eye (Lond); 2021 Feb; 35(2):409-417. PubMed ID: 32265509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
    Ciulla TA; Hussain RM; Pollack JS; Williams DF
    Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
    Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
    Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.
    Zhu M; Chew JK; Broadhead GK; Luo K; Joachim N; Hong T; Syed A; Chang AA
    Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1217-25. PubMed ID: 25205618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
    Ross AH; Donachie PH; Sallam A; Stratton IM; Mohamed Q; Scanlon PH; Kirkpatrick JN; Johnston RL
    Eye (Lond); 2013 Jan; 27(1):56-64. PubMed ID: 23174752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
    Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
    Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Kim LN; Mehta H; Barthelmes D; Nguyen V; Gillies MC
    Retina; 2016 Aug; 36(8):1418-31. PubMed ID: 27388744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.
    Feltgen N; Bertelmann T; Bretag M; Pfeiffer S; Hilgers R; Callizo J; Goldammer L; Bemme S; Hoerauf H
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):923-934. PubMed ID: 28102456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
    Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
    J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab.
    Khurana RN; Chang L; Day BM; Ghanekar A; Stoilov I
    Ophthalmol Retina; 2020 Aug; 4(8):760-766. PubMed ID: 32387055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.